重叠延伸PCR法克隆人脂联素基因及其在毕赤酵母中表达

利用重叠延伸PCR法克隆出人脂联素基因, 连接至克隆载体pGEM-T中, 转化大肠杆菌DH5a, 通过测序对其进行序列分析后, 进一步构建毕赤酵母表达载体pPIC3.5K-ADPN, 通过电击法转化毕赤酵母GS115, 转化的重组酵母菌用甲醇诱导外源基因表达。经PCR、Southern blotting鉴定, 获得了重组毕赤酵母菌株; 经甲醇诱导人脂联素基因表达, Western blotting杂交鉴定证明人脂联素基因已经在毕赤酵母中成功表达。结果表明重叠延伸PCR法准确方便克隆出人脂联素基因, 在30oC, 1%甲醇诱导48 h, 人脂联素基因在巴斯德毕赤酵母中的表达最佳。     

球状脂联素激活血管内皮细胞核因子-κB的表达

脂联素是由脂肪细胞合成并分泌的脂肪因子之一,因其可以调节细胞对胰岛素的敏感性,具有抗炎和抗动脉粥样硬化的作用而受到高度关注。血清脂联素以三聚体、六聚体和高分子量形式存在,球状脂联素作为脂联素的蛋白水解产物和脂联素的主要活性片段也存在于人血循环中。但是,不同形式的脂联素的生物学功能还存在争议。重组球状脂联素可以减轻胰岛素抵抗,促进骨骼肌和培养的肌细胞脂肪酸氧化。但人们注意到高分子量脂联素与总脂联素的比值而不是脂联素的绝对量决定了人和啮齿类动物对胰岛素的敏感性。2型糖尿病和冠心病患者血中高分子量脂联素选择性降低。最近Yoshiyuki等发现,球状脂联素可以激活血管内皮细胞核因子-κB（NF-κB）,诱导促炎症因子和粘附分子基因的表达。     

脂联素及其球状区在大肠杆菌中的可溶性表达

目的:克隆表达有生物学活性的脂联素及其球状区蛋白,并制备抗体。方法:以pQE30-adiponectin质粒为模板,PCR扩增脂联素及其球状区蛋白基因片段,插入pGEX-4T-2载体,转化大肠杆菌BL21后获得表达,用GSTrap柱亲和纯化可溶性表达的蛋白。用纯化的蛋白免疫家兔制备多抗,Westernblot鉴定抗体与人血清中脂联素的反应性。结果:PCR扩增脂联素基因片段长约710bp,脂联素球状区基因片段长约430bp。表达的GST-脂联素融合蛋白表观Mr约51000,GST-脂联素球状区融合蛋白表观Mr约42000,纯化后纯度高于90%。免疫产生的抗体与人血清中的脂联素能特异性结合。结论:表达获得的脂联素蛋白和制备的抗体为脂联素的检测及对其功能的研究奠定了基础。     

gAd重组质粒的构建及其在大肠杆菌中的表达

为了建立人脂联素球状结构域(gAd)原核高效表达体系,分离纯化gAd并检测其生物活性,从淋巴细胞中提取人基因组DNA,PCR扩增出含有脂联素编码序列的片段,通过T-A克隆的方法克隆入pMD18-T载体中,然后设计适当的引物引入起始密码、终止密码以及相应的酶切位点,把脂联素球状结构域(gAd)基因亚克隆到表达载体pBV220,将序列鉴定正确的重组质粒转化入大肠杆菌DH5α中,用42℃温控诱导目的蛋白的表达;超声破菌,分离纯化包涵体,8mol/L尿素溶解,采用梯度稀释法复性重组蛋白,动物实验测定其活性。结果在大肠杆菌中成功实现了gAd稳定的以包涵体形式的高效表达,表达量约占全菌蛋白的20%,经聚丙烯酰胺凝胶电泳鉴定分离得到的包涵体具有较高纯度,复性后具有降低家兔血糖和游离脂肪酸的作用。为进一步研究gAd的生物学活性、作用机制奠定了基础。     

地鳖虫纤溶活性蛋白cDNA序列克隆与毕赤酵母表达

依据已报道的地鳖虫成熟肽cDNA序列设计引物,通过RT-PCR法从地鳖虫(Eupolyphage sinensis Walker)中克隆得到675 bp地鳖虫纤溶活性蛋白 (fibrinolytic protein,EFP)成熟肽编码序列.将此片段克隆到表达载体pPICZα-A中,转化毕赤酵母GS115,甲醇诱导表达得到重组表达蛋白,经SDS-PAGE电泳和活性鉴定,表明重组EFP在毕赤酵母中均获得表达,重组表达蛋白相对分子质量为28.2 kD,表达产物分子质量与理论分子质量相符.重组蛋白在毕赤酵母中以分泌形式表达,具有纤溶活性.     

人精氨酸酶在毕赤酵母的高效表达、纯化和活性研究

目的：人精氨酸酶（Arginase, Arg）的基因arg在毕赤酵母高效分泌表达,建立相应纯化工艺路线,研究重组人精氨酸酶的活性。方法：将人精氨酸酶基因arg按正确的阅读框架插入到毕赤酵母表达载体pPIC9α信号肽基因后,构建得到重组毕赤酵母表达质粒。转化毕赤酵母GS115筛选高表达菌株。结果：成功构建了酵母表达载体pPIC-Arg,转化毕赤酵母GS115后筛选到分泌表达目的蛋白Arg的菌株,目标蛋白可以分泌到培养基中。经过膜过滤和凝胶过滤层析对培养基上清进行纯化,即可获得纯度达到95%的活性产物。活性测定表明,纯化的Arg比活性为310 IU/mg。结论：成功构建了Arg的毕赤酵母高效表达菌种,建立了目标物质的分离纯化工艺。     

内切葡聚糖酶基因在大肠杆菌与毕赤酵母中的表达

根据绿色木霉(Trichoderma viride)WL 0422菌株内切葡聚糖酶基因egⅡ的cDNA序列,设计特异引物,以重组质粒pTG19-T-egⅡ为模板,扩增得到全长1 194bp的egⅡ成熟肽cDNA片段.将该片段分别克隆到大肠杆菌(Escherichia coil)表达载体pET-28a( )和毕赤酵母(Pichia pastoris)表达载体pPIC9K中,并在大肠杆菌Rosset(DE3)和毕赤酵母GS115中进行了表达.重组大肠杆菌表达蛋白占菌体总蛋白的15%,表达产物无内切葡聚糖酶活性.重组毕赤酵母经甲醇诱导实现了分泌表达,在摇床水平上酶活性达到2 788U/ml.酶学性质分析表明,该酶作用的最适pH为4.5,pH 3.5～6.0范围内酶活性保留在80%以上;最适温度为50℃,55℃以下酶的稳定性在90%以上.     

OSF1在毕赤酵母菌中的分泌表达及其生物活性

为了研究人成骨细胞刺激因子(Human osteoblast-stimulating factor,OSF-1)的生物学活性,构建OSF-1高效毕赤酵母表达菌株并表达纯化具有生物活性的OSF-1。首先通过全基因人工合成的方法合成人osf-1基因,并克隆至毕赤酵母分泌表达载体pPIC9K,构建重组表达质粒pPIC9K/osf-1,线性化后电转化酵母宿主菌GS115,构建P.pastoris GS115/pPIC9K/osf-1,经MD、G418-YPD平板和PCR法筛选,获得多拷贝转化子。阳性表达菌株在25℃,经1%的甲醇诱导表达96 h,重组蛋白的表达量达到最大。经SDS-PAGE电泳分析所表达的重组蛋白约为18 kDa,与人成骨细胞刺激因子相符。表达上清经SP-Sephadex C-50离子交换层析进行纯化,得到纯度达98%以上的OSF-1。Western blotting鉴定该蛋白对人成骨细胞刺激因子抗体具有良好的抗原性。生物活性测定表明提纯的OSF-1能促进鼠成骨细胞MC3T3-E1的增殖和分化。利用重组毕赤酵母高效分泌表达了有生物活性的OSF-1,为进一步开展其抗骨质疏松活性研究及产业化开发奠定了基础。     

无标签人源性脂联素球状结构的表达、纯化与活性检测

目的:利用基工程方法构建无标签人性脂联素球状结构(gAd)基的核表达载体,并对重组蛋白进行诱导表达、纯化及鉴定.方法:从正常人脂肪组织里提取总 RNA,反转录合成 cDNA,经 PCR 扩增、酶切后连入pET-22b(+)载体构建重组质粒 pET-22b(+)-gAd,转化大肠杆菌 BL21(DE3)感受态细胞,经低温、低浓度 IPTG 诱导使其可溶性表达,采用硫酸铵沉淀、凝胶过滤层析和离子交换层析三步分离纯化,得到不带任何标签的人性gAd;运用 SDS-PAGE、Western 印迹、HPLC 对重组蛋白进行鉴定,通过对 AMP 激活的蛋白激酶(AMPK)的磷酸化水平检测纯化蛋白的生物学活性.结果:构建了核表达载体 pET-22b(+)-gAd,实现了人性 gAd 在核细胞中的可溶性表达,纯化的蛋白经 SDS-PAGE 和 Western 印迹分析证实为 gAd,HPLC 分析蛋白纯度达到95%以上;通过对 AMPK磷酸化水平的检测,证明纯化的 gAd 具有高生物学活性.结论:重组表达和纯化了无标签、高生物学活性的人性脂联素球状结构,为其进一步的理论研究、生产开发奠定了基础.     

金针菇免疫调节蛋白基因fip-fve在毕赤酵母GS115中诱导型和组成型表达

为获得稳定来源并且具有生物学活性的重组金针菇免疫调节蛋白(Fip-fve),将fip-fve基因转至毕赤酵母GS115中进行诱导型和组成型表达。用PCR方法从金针菇子实体基因组DNA中扩增fip-fve基因,连接至pPIC9构建诱导型表达载体pPIC9-FIP-fve,从毕赤酵母基因组DNA中扩增三磷酸甘油醛脱氢酶启动子(pgap),替换pPIC9-FIP-fve上乙醇氧化酶启动子(paox1)构建组成型表达载体pPIC9-PGAP-FIP-fve。将线性化的两种表达载体用PEG法转化毕赤酵母GS115,经组氨酸缺失培养基筛选和酵母菌落PCR鉴定后进行表达。结果表明,重组Fip-fve在以甲醇(1%,V/V)为碳源进行诱导型表达4 d达到最高,粗蛋白表达量为158.2 mg/L,在以葡萄糖(10%)和甘油(1%,V/V)为碳源进行组成型分别在表达第4天和第5天达到最高,粗蛋白分别为46.3 mg/L和29.5 mg/L。SDS-PAGE及Western blotting证明重组Fip-fve已正确表达,血细胞凝集活性检测初步证明重组Fip-fve具有良好生物学活性。     

Histone H1t is not replaced by H1.1 or H1.2 in pachytene spermatocytes or spermatids of H1t-deficient mice

The linker histone gene H1t is exclusively expressed in the mammalian testis. In former experiments we have shown that H1.1 and H1.2 histone gene expression is significantly enhanced in testis of adult H1t deficient mice. In this report we have quantified the mRNA of different H1 genes in 9-day- and 20-day-old wild type and H1t knock out mice. In addition, we have analysed the distribution of H1.1 and H1.2 protein by immunofluorescent staining in spread male germ cells. The aim of this work was to answer the question whether H1t can be replaced during spermatogenesis by H1.1 or H1.2. In our experiments we could not detect elevated levels of H1.1 or H1.2 in pachytene spermatocytes or haploid cells of H1t deficient testis. Therefore, in these cells, H1t seems not to be replaced by H1.1 or H1.2.     

Anticancer drugs induce hypomethylation of the acetylcholinesterase promoter via a phosphorylated-p38-DNMT1-AChE pathway in apoptotic hepatocellular carcinoma cells

Apoptosis, also known as programmed cell death, plays an essential role in eliminating excessive, damaged or harmful cells. Previous work has demonstrated that anticancer drugs induce cell apoptosis by inducing cytotoxicity. In recent years, several reports demonstrated modulated expression of DNA methyltransferases 1 (DNMT1) and acetylcholinesterase (AChE) in a variety of tumors. In this study, we showed that the expression of DNMT1 was decreased and the methylation of CpGs in the promoter of AChE was reduced in anticancer drugs-induced apoptotic hepatocellular carcinoma cells. Silencing of DNMT1 expression by AZA or RNA interference (RNAi) restored AChE production and inhibition of AChE expression by RNAi protected HCC cells from anticancer drugs-induced apoptosis. Furthermore, we demonstrated that the regulation of AChE by DNMT1 was involved in the phosphorylated p38 pathway in anticancer drugs-induced apoptosis. In addition, immunohistochemical staining showed that P-p38, DNMT1 and AChE were aberrantly expressed in a subset of HCC tumors. Taken together, we demonstrated the regulation of AChE by DNMT1 and further, we found that this regulation was involved in the phosphorylated p38 pathway in anticancer drugs-induced apoptosis.     

Nuclear thioredoxin-1 is required to suppress cisplatin-mediated apoptosis of MCF-7 cells

Different cell line with increased thioredoxin-1 (Trx-1) showed a decreased or increased sensitivity to cell killing by cisplatin. Recently, several studies found that the subcellular localization of Trx-1 is closely associated with its functions. In this study, we explored the association of the nuclear Trx-1 with the cisplatin-mediated apoptosis of breast cancer cells MCF-7. Firstly, we found that higher total Trx-1 accompanied by no change of nuclear Trx-1 can not influence apoptosis induced by cisplatin in MCF-7 cells transferred with Trx-1 cDNA. Secondly, higher nuclear Trx-1 accompanied by no change of total Trx-1 can protect cells from apoptosis induced by cisplatin. Thirdly, high nuclear Trx-1 involves in the cisplatin-resistance in cisplatin-resistive cells. Meanwhile, we found that the mRNA level of p53 is closely correlated with the level of nuclear Trx-1. In summary, we concluded that the nuclear Trx-1 is required to resist apoptosis of MCF-7 cells induced by cisplatin, probably through up-regulating the anti-apoptotic gene, p53.     

Feedback Regulation of SIN by Etd1 and Rho1 in Fission Yeast

In fission yeast, the septation initiation network (SIN) is thought to promote cytokinesis by downstream activation of Rho1, a conserved GTPase that controls cell growth and division. Here we show that Etd1 and PP2A-Pab1, antagonistic regulators of SIN, are Rho1 regulators. Our genetic and biochemical studies indicate that a C-terminal region of Etd1 may activate Rho1 by directly binding it, whereas an N-terminal domain confers its ability to localize at the growing tips and the division site where Rho1 functions. In opposition to Etd1, our results indicate that PP2A-Pab1 inhibits Rho1. The SIN cascade is upstream-regulated by the Spg1 GTPase. In the absence of Etd1, activity of Spg1 drops down prematurely, thereby inactivating SIN. Interestingly, we find that ectopic activation of Rho1 restores Spg1 activity in Etd1-depleted cells. By using a cytokinesis block strategy, we show that Rho1 is essential to feedback-activate Spg1 during actomyosin ring constriction. Therefore, activation of Spg1 by Rho1, which in turn is regulated by Etd1, uncovers a novel feedback loop mechanism that ensures SIN activity while cytokinesis is progressing.     

Kinetics of the ceramide kinase inhibitor K1, a suppressor of mast-cell activation

In a previous study, we synthesized a novel inhibitor of ceramide kinase, K1. In this study, we determined that inhibition by K1 is non-competitive and that four intact six-membered rings are important to the inhibitory activity. Furthermore, we identified an effective in vivo concentration for K1, at which it did not influence any cellular lipid synthesis other than that of ceramide 1-phosphate (C1P) using RBL-2H3 cells, and found that K1 suppressed the activation of mast cells.     

The polyomavirus major capsid protein VP1 interacts with the nuclear matrix regulatory protein YY1

Polyomavirus reaches the nucleus in a still encapsidated form, and the viral genome is readily found in association with the nuclear matrix. This association is thought to be essential for viral replication. In order to identify the protein(s) involved in the virus-nuclear matrix interaction, we focused on the possible roles exerted by the multifunctional cellular nuclear matrix protein Yin Yang 1 (YY1) and by the viral major capsid protein VP1. In the present work we report on the in vivo association between YY1 and VP1. Using the yeast two-hybrid system we demonstrate that the VP1 and YY1 proteins physically interact through the D-E region of VP1 and the activation domain of YY1.     

Frequency-dependent modulation of KCNQ1 and HERG1 potassium channels

To obtain information about a possible frequency-dependent modulation of HERG1 and hKCNQ1 channels, we performed heterologous expression in Xenopus laevis oocytes. Channel activation was obtained by voltage protocols roughly imitating cardiac action potentials at frequencies of 1, 3, 5.8, and 8.3Hz. The activity of HERG1 channels was inhibited down to 65% at high frequencies. In contrast, hKCNQ1 channel activity was increased up to 525% at high frequencies. The general frequency-dependent modulation of the channels was unaffected by both co-expression of hKCNQ1 and HERG1 channels, and by the presence of the beta-subunits KCNE1 and KCNE2. In addition, the functional role of HERG1 in native guinea pig cardiac myocytes was demonstrated at different pacing frequencies by application of 10microM of the new HERG1 activator, NS1643. In conclusion, we have demonstrated that HERG1 and hKCNQ1 channels are inversely modulated by stimulation frequency.     

Microbial Transformation of ML-236B (Compactin) to M3, a Mammalian Metabolite of ML-236B

In a previous study, we synthesized a novel inhibitor of ceramide kinase, K1. In this study, we determined that inhibition by K1 is non-competitive and that four intact six-membered rings are important to the inhibitory activity. Furthermore, we identified an effective in vivo concentration for K1, at which it did not influence any cellular lipid synthesis other than that of ceramide 1-phosphate (C1P) using RBL-2H3 cells, and found that K1 suppressed the activation of mast cells.